{"product_id":"immune-dysfunction-and-immunotherapy-in-heart-disease-isbn-9781405155687","title":"Immune Dysfunction and Immunotherapy in Heart Disease","description":"Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction.\u003cbr\u003e \u003cp\u003eThe outstanding editor team of two internationally recognized immunologists -- Ronald Watson, who has studied heart disease in immune dysfunction for a decade and has a patent for an immunotherapy of heart disease by immune regulation, and Douglas Larson, whose experience in cardiac transplantation immunology has provided the foundation for research into novel therapeutics for heart failure and hypertension – makes Immune Dysfunction and Immunotherapy in Heart Disease the definitive reference to the state of the science in this area.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThe four parts of the book address:\u003cbr\u003e \u003c\/p\u003e \u003cul\u003e \u003cli style=\"list-style: none\"\u003e\n\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Disease: Induction by Physiological Changes\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Promoting CVD: Induction by Transplantation Drugs\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Dysfunction: Induction or Prevention by Cardiotherapeutic Drugs\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Disease: Induction by Pathogens\u003c\/li\u003e \u003c\/ul\u003e \u003cbr\u003e \u003cp\u003eBoth researchers and practitioners will find this authoritative volume an excellent source of information on novel immune targeted therapeutics.\u003c\/p\u003e  Contributors. \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003eAbout the Editors.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Immune dysfunction leading to.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eheart disease: induction by.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ephysiological changes\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e1 Immunosuppression by ultraviolet light-B.\u003c\/p\u003e \u003cp\u003eradiation: amediator of cardiac remodeling.\u003c\/p\u003e \u003cp\u003eSherma Zibadi (The University of Arizona), Douglas F. Larson (Sarver Heart Center In the School of Medicine) \u0026amp; Ronald.\u003c\/p\u003e \u003cp\u003eRoss Watson (Sarver Heart Center in the School of Medicine).\u003c\/p\u003e \u003cp\u003e2 Immune mechanisms in pediatric.\u003c\/p\u003e \u003cp\u003ecardiovascular disease.\u003c\/p\u003e \u003cp\u003eWendy A. Luce (Childrens Research Institute), Mandar S. Joshi (Center for Cardiovascular Medicine, Columbus), Timothy M.\u003c\/p\u003e \u003cp\u003eHoffman, Timothy (Columbus Children's Heart Center), F. Feltes (Childrens Research Institute) \u0026amp; John Anthony.\u003c\/p\u003e \u003cp\u003eBauer (Wexner Child Hospital, Ohio State University).\u003c\/p\u003e \u003cp\u003e3 Heart failure–role of autoimmunity.\u003c\/p\u003e \u003cp\u003eUrs Eriksson (Universitatsspital).\u003c\/p\u003e \u003cp\u003e4 Immune basis of hypertension in humans.\u003c\/p\u003e \u003cp\u003eKatherine Horak (Sarver Heart Center, The University of Arizona) \u0026amp; Douglas F. Larson (Sarver Heart Center In the School of Medicine).\u003c\/p\u003e \u003cp\u003e5 Immune dysregulation: potential mediator of.\u003c\/p\u003e \u003cp\u003emetabolic syndrome-induced cardiac.\u003c\/p\u003e \u003cp\u003eremodeling.\u003c\/p\u003e \u003cp\u003eSherma Zibadi (The University of Arizona), Douglas F. Larson (Sarver Heart Center In the School of Medicine) \u0026amp; Ronald.\u003c\/p\u003e \u003cp\u003eRoss Watson (Sarver Heart Center in the School of Medicine).\u003c\/p\u003e \u003cp\u003e6 T helper 2 cell cytokines in remodeling of.\u003c\/p\u003e \u003cp\u003eaortic wall.\u003c\/p\u003e \u003cp\u003eW. L. Chan (William Harvey Research Institute).\u003c\/p\u003e \u003cp\u003e7 Effects of TNF- on cardiac function.\u003c\/p\u003e \u003cp\u003eBo Yang (University of Arizona) \u0026amp; Douglas F. Larson (Sarver Heart Center In the School of Medicine).\u003c\/p\u003e \u003cp\u003e8 Immunosuppression in promotion of cardiac.\u003c\/p\u003e \u003cp\u003eallograft vasculopathy.\u003c\/p\u003e \u003cp\u003eFarzad Moien-Afshari (University of British Columbia), Jonathan Choy (Department of Pharmacology and Therapeutics), Bruce.\u003c\/p\u003e \u003cp\u003eM. McManus (Department of Pharmacology and Therapeutics) \u0026amp; Ismail Laher (University of British Columbia).\u003c\/p\u003e \u003cp\u003e9 Immunotherapy for left.\u003c\/p\u003e \u003cp\u003eventricular dysfunction after.\u003c\/p\u003e \u003cp\u003eheart transplantation.\u003c\/p\u003e \u003cp\u003eCharles E. Canter (Washington University School of Medicine).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Immune dysfunction promoting.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCVD: induction by transplantation.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003edrugs\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e10 Immunomodulating therapy in chronic heart.\u003c\/p\u003e \u003cp\u003efailure.\u003c\/p\u003e \u003cp\u003eLars Gullestad (Department of Cardiology, University of Oslo, N-0027 Oslo, Norway).\u003c\/p\u003e \u003cp\u003e, Jan Kristian Dam°as (Research Institute for Internal Medicine),.\u003c\/p\u003e \u003cp\u003eArne Yndestad (Research Institute for Internal Medicine, University of Oslo) \u0026amp; P°al Aukrust (Rikshospitalet).\u003c\/p\u003e \u003cp\u003e11 Statins in atherosclerosis: role of immune.\u003c\/p\u003e \u003cp\u003eregulation.\u003c\/p\u003e \u003cp\u003eClaire Arnaud \u0026amp; Fran¸cois Mach (Foundation for Medical Research).\u003c\/p\u003e \u003cp\u003e12 ACE inhibitors as immunomodulators:.\u003c\/p\u003e \u003cp\u003etreatment of cardiovascular disease.\u003c\/p\u003e \u003cp\u003eChristina Grothusen (Dept. of Cardiology and Angiology) \u0026amp; Bernhard Schieffer (Department of Cardiology and Angiology).\u003c\/p\u003e \u003cp\u003e13 Treatment of heart failure by anticytokine.\u003c\/p\u003e \u003cp\u003etherapies.\u003c\/p\u003e \u003cp\u003eDonna L. Vredevoe (University of California, Los Angeles) \u0026amp; Julia R. Gage (Kendle International, Inc., Thousand Oaks, CA).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Immune dysfunction leading to.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eheart dysfunction: induction or.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eprevention by cardiotherapeutic.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003edrugs\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e14 Pathogenesis of cardiovascular complications.\u003c\/p\u003e \u003cp\u003ein the acquired immunodeficiency.\u003c\/p\u003e \u003cp\u003esyndrome.\u003c\/p\u003e \u003cp\u003eGiuseppe Barbaro (University “La Sapienza”).\u003c\/p\u003e \u003cp\u003e15 Cytokines and T cell-mediated responses in.\u003c\/p\u003e \u003cp\u003eautoimmune myocarditis.\u003c\/p\u003e \u003cp\u003eJin Zhang (The Proctor and Gamble Company).\u003c\/p\u003e \u003cp\u003e16 Drugs of abuse: accentuation of.\u003c\/p\u003e \u003cp\u003eimmunomodulation of viral myocarditis.\u003c\/p\u003e \u003cp\u003eOana Madalina Petrescu (Caritas St. Elizabeth's Medical Center, Boston) \u0026amp; James P. Morgan (Department of Medicine).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Immune dysfunction leading to.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eheart disease: induction by.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003epathogens\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e17 Osteopontin: the link between the immune.\u003c\/p\u003e \u003cp\u003esystem and cardiac remodeling.\u003c\/p\u003e \u003cp\u003eSamira Najmaii (Sarver Heart Center, The University of Arizona), Qianli Yu (Sarver Heart Center) \u0026amp; Douglas.\u003c\/p\u003e \u003cp\u003eF. Larson (Sarver Heart Center In the School of Medicine).\u003c\/p\u003e \u003cp\u003e18 Inflammatory immune activation in heart.\u003c\/p\u003e \u003cp\u003efailure patients: therapeutic implications.\u003c\/p\u003e \u003cp\u003eMohammad Abraham Kazemizadeh Gol (University of Minnesota) \u0026amp;.\u003c\/p\u003e \u003cp\u003eMohsen Araghi-Niknam (CRM Clinical Research).\u003c\/p\u003e \u003cp\u003e19 Role of innate immune dysregulation in.\u003c\/p\u003e \u003cp\u003ediabetic heart failure.\u003c\/p\u003e \u003cp\u003eBetsy B. Dokken (University of Arizona School of Medicine) \u0026amp; Paul F. McDonagh (Allan C. Hudson and Helen Lovaas Endowed Chair of Vascular Biology and Coagulation).\u003c\/p\u003e \u003cp\u003e20 Tolerance in heart transplantation: current.\u003c\/p\u003e \u003cp\u003eand future role.\u003c\/p\u003e \u003cp\u003eKimberly Gandy (University of Arizona), Jos Domen (Department of Surgery) \u0026amp; Jack.\u003c\/p\u003e \u003cp\u003eCopeland (Department of Surgery).\u003c\/p\u003e \u003cp\u003e21 Neutralization of Th2 cytokines in therapy of.\u003c\/p\u003e \u003cp\u003ecardiovascular pathology.\u003c\/p\u003e \u003cp\u003eA. Mandel (Director of Fundamental \u0026amp; Medical Research) \u0026amp; A. E. Bolton (Vasogen Ireland Limited).\u003c\/p\u003e \u003cp\u003e22 Anti-inflammatory immune therapy in heart.\u003c\/p\u003e \u003cp\u003edisease.\u003c\/p\u003e \u003cp\u003eDavid Chen (The Methodist DeBakey Heart Center), Christian Assad-Kottner (The Methodist DeBakey Heart Center),.\u003c\/p\u003e \u003cp\u003eFrancisco J. Cordova (The Methodist DeBakey Heart Center), Carlos Orrego (The Methodist DeBakey Heart Center) \u0026amp;.\u003c\/p\u003e \u003cp\u003eGuillermo Torre-Amione (The Methodist DeBakey Heart Center).\u003c\/p\u003e \u003cp\u003e23 Cholesterol, interleukin-6 inflammation, and.\u003c\/p\u003e \u003cp\u003eatherosclerosis—role of statins,.\u003c\/p\u003e \u003cp\u003ebisphosphonates, and plant polyphenols in.\u003c\/p\u003e \u003cp\u003eatherosclerosis and other diseases of.\u003c\/p\u003e \u003cp\u003eaging.\u003c\/p\u003e \u003cp\u003eSota Omoigui (L. A. Pain Clinic - medcinehouse.com).\u003c\/p\u003e \u003cp\u003e24 Autoimmune myocarditis: treatment with.\u003c\/p\u003e \u003cp\u003eanti-T-cell antibodies.\u003c\/p\u003e \u003cp\u003eZofia T. Bilin´ska \u0026amp; Witold Ruzytto.\u003c\/p\u003e \u003cp\u003e25 Immunosuppressive therapy to counter.\u003c\/p\u003e \u003cp\u003ecardiac allograft vasculopathy.\u003c\/p\u003e \u003cp\u003eCarl V. Leier (Division of Cardiovascular Medicine).\u003c\/p\u003e \u003cp\u003e26 Role of oral pathogens in the pathogenesis of.\u003c\/p\u003e \u003cp\u003ecoronary heart disease.\u003c\/p\u003e \u003cp\u003ePalle Holmstrup (University of Copenhagen, Department of Periodontology).\u003c\/p\u003e \u003cp\u003e27 Myocardial regenerative potential by stem cell.\u003c\/p\u003e \u003cp\u003etransplant.\u003c\/p\u003e \u003cp\u003eYinhong Chen (Geron Corporation), Catherine A. Priest (Geron Corporation) \u0026amp;.\u003c\/p\u003e \u003cp\u003eJoseph D. Gold (Director of Stem Cell Biology and Research Questions).\u003c\/p\u003e \u003cp\u003e28 Bioflavanoids and dietary anti-inflammatory.\u003c\/p\u003e \u003cp\u003eactions: role in cardiovascular diseases.\u003c\/p\u003e \u003cp\u003eSimin Bolourchi-Vaghefi (University of North Florida College of Health) \u0026amp; Amy Galena (Clinical dietitian).\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e  Dr. Larson and Dr. Watson have worked together researching the role of immune and cytokine dysfunction in heart disease for 8 years. They have been and currently are funded to do such research by grants from the U.S. National Institute of Heart, Lung and Blood, the American Heart Foundation, companies and private foundations. Dr. Watson has edited 62 scientific books, including several dealing with heart disease and conditions such as aging and AIDS that promote immune dysfunction as well as heart disease. Dr. Larson directs the Center’s organ perfusion program as well as its Master degree in pharmacology and toxicology for perfusion students.\u003cbr\u003e \u003cp\u003e ____________________________________________________________________\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eRonald Ross Watson Ph.D.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eProfessor Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health and the Sarver Heart Center in the School of Medicine, University of Arizona, P. O. Box 245155, 1501 N. Campbell Avenue, Tucson, AZ 85749.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e(520) 626 2850, Fax (520) 626 6093 rwatson@u.arizona.edu\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e ____________________________________________________________________\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eDouglas F. Larson Ph.D.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eProfessor Surgery and the Sarver Heart Center in the School of Medicine, University of Arizona, P. O. Box 245066, 1501 N. Campbell Avenue, Tucson, AZ 85749. (520) 626 6494 dflarson@email.arizona.edu\u003c\/p\u003e  Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction.\u003cbr\u003e \u003cp\u003eThe outstanding editor team of two internationally recognized immunologists -- Ronald Watson, who has studied heart disease in immune dysfunction for a decade and has a patent for an immunotherapy of heart disease by immune regulation, and Douglas Larson, whose experience in cardiac transplantation immunology has provided the foundation for research into novel therapeutics for heart failure and hypertension – makes Immune Dysfunction and Immunotherapy in Heart Disease the definitive reference to the state of the science in this area.\u003cbr\u003e \u003c\/p\u003e \u003cp\u003eThe four parts of the book address:\u003cbr\u003e \u003c\/p\u003e \u003cul\u003e \u003cli style=\"list-style: none\"\u003e\n\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Disease: Induction by Physiological Changes\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Promoting CVD: Induction by Transplantation Drugs\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Dysfunction: Induction or Prevention by Cardiotherapeutic Drugs\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eImmune Dysfunction Leading to Heart Disease: Induction by Pathogens\u003c\/li\u003e \u003c\/ul\u003e \u003cbr\u003e \u003cp\u003eBoth researchers and practitioners will find this authoritative volume an excellent source of information on novel immune targeted therapeutics.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989403123941,"sku":"NP9781405155687","price":204.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405155687.jpg?v=1761783974","url":"https:\/\/k12savings.com\/products\/immune-dysfunction-and-immunotherapy-in-heart-disease-isbn-9781405155687","provider":"K12savings","version":"1.0","type":"link"}